Acquired Amegakaryocytic Thrombocytopenia
Symptoms, Doctors, Treatments, Advances & More

Acquired Amegakaryocytic Thrombocytopenia Overview

Save information for later
Sign Up

Learn About Acquired Amegakaryocytic Thrombocytopenia

Who are the top Acquired Amegakaryocytic Thrombocytopenia Local Doctors?
Elite in Acquired Amegakaryocytic Thrombocytopenia
Dr. Vilmarie Rodriguez
General Practice
Elite in Acquired Amegakaryocytic Thrombocytopenia
Dr. Vilmarie Rodriguez
General Practice
Bayamon, PR 
787-730-3446
Languages Spoken:
English
See accepted insurances

Vilmarie Rodriguez is a primary care provider, practicing in General Practice in Bayamon, Puerto Rico. Dr. Rodriguez is rated as an Elite provider by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Acquired Amegakaryocytic Thrombocytopenia, Renal Vein Thrombosis, Warts, and Axial Spondyloarthritis (AxSpA).

Elite in Acquired Amegakaryocytic Thrombocytopenia
Manuela Germeshausen
Elite in Acquired Amegakaryocytic Thrombocytopenia
Manuela Germeshausen
Referral may be required
Carl Neuberg Str. 1, 
Hannover, NI, DE 

Manuela Germeshausen practices practicing medicine in Hannover, Germany. Ms. Germeshausen is rated as an Elite expert by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Acquired Amegakaryocytic Thrombocytopenia, Agranulocytosis, Cyclic Neutropenia, and Severe Congenital Neutropenia.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Acquired Amegakaryocytic Thrombocytopenia
Matthias Ballmaier
Elite in Acquired Amegakaryocytic Thrombocytopenia
Matthias Ballmaier
Referral may be required
Carl Neuberg Str. 1, 
Hannover, NI, DE 

Matthias Ballmaier practices practicing medicine in Hannover, Germany. Mr. Ballmaier is rated as an Elite expert by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. He is also highly rated in 1 other condition, according to our data. His clinical expertise encompasses Acquired Amegakaryocytic Thrombocytopenia, Thrombocytopenia, Aplastic Anemia, and Paroxysmal Cold Hemoglobinuria.

View All Doctors
What are the latest Acquired Amegakaryocytic Thrombocytopenia Clinical Trials?
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Enrollment Status: Recruiting
Publish Date: June 03, 2026
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2

Summary: A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing o...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation
Who is this study for: Patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drugs: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Study Phase: Phase 2

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 10, 2022
Published By: Genetic and Rare Diseases Informnation Center